Irrisept Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Location

GA US

Primary Industry

Medical Devices & Equipment

About

Based in Georgia, US, Irrimax Corporation, doing business as Irrisept develops Irrisept, a jet lavage used for wound debridement and cleansing that helps loosen and remove debris without harming underlying tissue. In August 2024, ARCHIMED acquired Irrimax Corporation from Decathlon Capital Partners. As of September 2024, the company is led by CEO Mark Alvarez. Irrimax's primary product, Irrisept, is a self-contained jet lavage system to deliver low-pressure wound irrigation. It is used in both acute and post-acute care settings, helping remove foreign materials, cellular debris, and bacterial contaminants from wounds. The bottled solution contains 0.05% chlorhexidine gluconate to prevent a broad spectrum of microorganisms, including bacteria, fungi, and some viruses. The low concentration of CHG in Irrisept minimizes cytotoxicity while maintaining its function as a cleaning agent. The product line includes various sizes and configurations, such as the 450 mL and 150 mL Irrisept bottles, along with accessory kits like spikeable connection systems. The September 2024 acquisition will allow Irrimax Corporation to expand its business development and strengthen its market presence in the wound irrigation sector.

Primary Industry

Medical Devices & Equipment

Sub Industries

Medical Devices & Equipment

Website

www.irrisept.com

Verticals

Manufacturing

Company Stage

Mature

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.